ChromaDex Corporation (CDXC): Price and Financial Metrics
GET POWR RATINGS... FREE!
CDXC POWR Grades
- CDXC scores best on the Quality dimension, with a Quality rank ahead of 72.62% of US stocks.
- CDXC's strongest trending metric is Momentum; it's been moving down over the last 178 days.
- CDXC's current lowest rank is in the Momentum metric (where it is better than 6.84% of US stocks).
CDXC Stock Summary
- CHROMADEX CORP's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 85.11% of US listed stocks.
- For CDXC, its debt to operating expenses ratio is greater than that reported by only 11.99% of US equities we're observing.
- The volatility of CHROMADEX CORP's share price is greater than that of 81.56% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to CHROMADEX CORP are OTLY, SMTI, INMD, PLAG, and HNST.
- Visit CDXC's SEC page to see the company's official filings. To visit the company's web site, go to www.chromadex.com.
CDXC Valuation Summary
- In comparison to the median Healthcare stock, CDXC's price/sales ratio is 36.36% lower, now standing at 1.4.
- CDXC's price/earnings ratio has moved down 0.4 over the prior 162 months.
Below are key valuation metrics over time for CDXC.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CDXC | 2022-09-09 | 1.4 | 4.7 | -3.5 | -3.6 |
| CDXC | 2022-09-08 | 1.4 | 4.7 | -3.5 | -3.6 |
| CDXC | 2022-09-07 | 1.4 | 4.7 | -3.5 | -3.6 |
| CDXC | 2022-09-06 | 1.4 | 4.6 | -3.4 | -3.5 |
| CDXC | 2022-09-02 | 1.4 | 4.6 | -3.4 | -3.6 |
| CDXC | 2022-09-01 | 1.4 | 4.7 | -3.4 | -3.6 |
CDXC Growth Metrics
- Its year over year revenue growth rate is now at 17.5%.
- Its 5 year price growth rate is now at 71.33%.
- Its 3 year price growth rate is now at -65.4%.
The table below shows CDXC's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-06-30 | 69.058 | -21.893 | -28.318 |
| 2022-03-31 | 70.025 | -25.956 | -27.487 |
| 2021-12-31 | 67.449 | -24.163 | -27.128 |
| 2021-09-30 | 65.135 | -19.197 | -27.9 |
| 2021-06-30 | 62.007 | -17.123 | -23.259 |
| 2021-03-31 | 59.595 | -10.784 | -21.404 |
CDXC's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CDXC has a Quality Grade of C, ranking ahead of 67.33% of graded US stocks.
- CDXC's asset turnover comes in at 1.115 -- ranking 18th of 682 Pharmaceutical Products stocks.
- MYGN, REPH, and ENDP are the stocks whose asset turnover ratios are most correlated with CDXC.
The table below shows CDXC's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 1.115 | 0.615 | -3.082 |
| 2021-06-30 | 1.178 | 0.612 | -2.751 |
| 2021-03-31 | 1.276 | 0.607 | -3.100 |
| 2020-12-31 | 1.545 | 0.595 | -2.616 |
| 2020-09-30 | 1.466 | 0.586 | -2.883 |
| 2020-06-30 | 1.361 | 0.577 | -2.841 |
CDXC Price Target
For more insight on analysts targets of CDXC, see our CDXC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $14.80 | Average Broker Recommendation | 1.3 (Strong Buy) |
CDXC Stock Price Chart Interactive Chart >
CDXC Price/Volume Stats
| Current price | $1.21 | 52-week high | $6.98 |
| Prev. close | $1.29 | 52-week low | $1.21 |
| Day low | $1.21 | Volume | 158,600 |
| Day high | $1.29 | Avg. volume | 448,803 |
| 50-day MA | $1.62 | Dividend yield | N/A |
| 200-day MA | $2.29 | Market Cap | 82.70M |
ChromaDex Corporation (CDXC) Company Bio
ChromaDex Corporation, a natural products company, through its subsidiaries, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company supplies bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. The company is based inIrvine, California.
Latest CDXC News From Around the Web
Below are the latest news stories about CHROMADEX CORP that investors may wish to consider to help them evaluate CDXC as an investment opportunity.
Sinopharm Xingsha to Introduce ChromaDex’s Tru Niagen® at Major Mainland China Trade Show, China International Natural Health & Nutrition Expo (NHNE)LOS ANGELES, September 19, 2022--ChromaDex Corp. (NASDAQ:CDXC) today announced that Sinopharm Xingsha will debut Tru Niagen® at the major mainland China trade show, China International Natural Health & Nutrition Expo (NHNE), which kicks off Tuesday, September 20, in Shanghai. NHNE is Asia’s largest expo on natural health and nutrition products, with over 100,000 distributors and retailers. It is considered the best platform to help global manufacturers of health food and nutrition promote their |
ChromaDex Announces Partnership with MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen® and Tru Niagen® PRO into BrazilLOS ANGELES, September 01, 2022--ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with MyPharma2Go to conduct cross-border sales of Tru Niagen® and Tru Niagen® PRO in Brazil, the first Latin American country to welcome the brand. Nicotinamide riboside or NR, the key ingredient in Tru Niagen®, is the world’s most efficient nicotinamide adenine dinucleotide (NAD+) precursor on the market, particularly over NMN (nicotinamide mononucleotide). MyPharma2Go, an American company focused on Br |
This Analyst Cuts ChromaDex's Price Target On Revised Growth TrajectoryEarlier this month, ChromaDex Corp (NASDAQ: CDXC) released Q2 earnings, indicating high single-digit revenue growth for FY22, driven by its global e-commerce business, offset by slower growth with new and existing partners. For FY22, the company expects approximately 60% gross margin, while selling and marketing expenses should be down as a percentage of net sales. ChromaDex also expects to report a roughly $1 million Y/Y increase in R&D and approximately a $6-7 million decrease in G&A expense, |
ChromaDex founder takes helm at Ginkgo Bioworks spinoutJust under a year after launching, a 'nutraceuticals' startup spun out of Ginkgo Bioworks Holdings Inc. has its first CEO. |
Ayana Bio Announces Appointment of Frank Jaksch as Chief Executive OfficerAyana Bio, the plant cell technology company making sustainable bioactives for consumer products, today announced the appointment of Frank Jaksch as the company's chief executive officer. Jaksch founded, was the longtime CEO and presently serves as Board Chair of health and wellness company ChromaDex, manufacturer of popular NAD product, Tru Niagen (Nasdaq: CDXC). |
CDXC Price Returns
| 1-mo | -18.24% |
| 3-mo | -34.95% |
| 6-mo | -53.82% |
| 1-year | -81.24% |
| 3-year | -70.70% |
| 5-year | -73.98% |
| YTD | -67.65% |
| 2021 | -22.08% |
| 2020 | 11.37% |
| 2019 | 25.66% |
| 2018 | -41.67% |
| 2017 | 77.64% |
Continue Researching CDXC
Want to do more research on ChromaDex Corp's stock and its price? Try the links below:ChromaDex Corp (CDXC) Stock Price | Nasdaq
ChromaDex Corp (CDXC) Stock Quote, History and News - Yahoo Finance
ChromaDex Corp (CDXC) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...